Buscar
Benitec Biopharma Inc
BNTCAñadir a la lista de seguimiento
12.040USD
+0.150+1.26%
Cierre 07-29 16:00（ET）Cotizaciones retrasadas 15 min
316.06MCap. mercado
PérdidaP/E TTM
Más Datos de Benitec Biopharma Inc Compañía
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Información de Benitec Biopharma Inc
Símbolo de cotizaciónBNTC
Nombre de la empresaBenitec Biopharma Inc
Fecha de salida a bolsaJul 11, 2012
Director ejecutivoBanks (Jerel A)
Número de empleados19
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 11
Dirección3940 Trust Way
CiudadHAYWARD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94545
Teléfono15107800819
Sitio Webhttps://benitec.com/
Símbolo de cotizaciónBNTC
Fecha de salida a bolsaJul 11, 2012
Director ejecutivoBanks (Jerel A)
Ejecutivos de Benitec Biopharma Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Benitec Biopharma Inc?
Los cinco principales accionistas de Benitec Biopharma Inc son: Ms. Megan Joan Boston
¿Cuántas instituciones poseen acciones de Benitec Biopharma Inc (BNTC)?
A fecha de 2026Q1, 131 instituciones poseen acciones de Benitec Biopharma Inc, con un valor de mercado combinado de aproximadamente 33.05M, lo que representa el 96.50% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 5127649.00.